Back to Journals » Research and Reports in Urology » Volume 4

Mirabegron – a selective ß3-adrenoreceptor agonist for the treatment of overactive bladder

Authors Bhide, Digesu A, Fernando, Khullar V

Received 1 May 2012

Accepted for publication 12 June 2012

Published 16 July 2012 Volume 2012:4 Pages 41—45

DOI https://doi.org/10.2147/RRU.S28930

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Alka A Bhide, G Alessandro Digesu, Ruwan Fernando, Vik Khullar

Department of Urogynaecology, St Mary's Hospital, London, United Kingdom

Abstract: Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been proposed to be effective for treating overactive bladder symptoms. Mirabegron has been shown to be superior to placebo for reducing the mean number of incontinence episodes per 24 hours and the mean number of micturitions per 24 hours. Side effects such as dry mouth were observed at similar or lower rates than those seen for placebo and antimuscarinics. Higher doses of mirabegron were associated with minor increases in pulse rate and mean blood pressure. Mirabegron offers a new alternative for treating overactive bladder in patients for which antimuscarinics are either not tolerated or not appropriate.

Keywords: beta-3 adrenoreceptor agonist, mirabegron, overactive bladder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]